Cargando…

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension

Detalles Bibliográficos
Autor principal:	Jung, Hae Ok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Cardiology 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110702/ https://www.ncbi.nlm.nih.gov/pubmed/30088355 http://dx.doi.org/10.4070/kcj.2018.0156

Ejemplares similares

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension
por: Kim, Kyung-Hee, et al.
Publicado: (2018)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
por: Wong, Alexandra K, et al.
Publicado: (2019)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
por: Monaco, Thomas J, et al.
Publicado: (2016)

Macitentan in the treatment of pulmonary hypertension in Gaucher’s disease
por: Taylan, Gökay, et al.
Publicado: (2020)

Macitentan treatment retards the progression of established pulmonary arterial hypertension in an animal model()
por: Temple, I.P., et al.
Publicado: (2014)

Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
por: Jansa, Pavel, et al.
Publicado: (2017)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Qin, Jinlv, et al.
Publicado: (2023)

Efficacy and safety of macitentan for pulmonary hypertension: A meta‐analysis
por: Du, Dan, et al.
Publicado: (2023)

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study)　― Protocol of a Multicenter Randomized Control Trial ―
por: Akagi, Satoshi, et al.
Publicado: (2021)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020)

Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series
por: Mathijssen, H., et al.
Publicado: (2020)

Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Real-World Safety and Clinical Outcomes of Macitentan in Asian Patients with Pulmonary Arterial Hypertension: A Prospective Multicenter Study
por: Jung, Su Young, et al.
Publicado: (2022)

Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study
por: Di Scala, Lilla, et al.
Publicado: (2022)

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis
por: Li, Jie, et al.
Publicado: (2022)

Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document
por: Rahaghi, Franck F., et al.
Publicado: (2017)

Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study
por: Escribano-Subias, Pilar, et al.
Publicado: (2020)

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up
por: Jariwala, Pankaj, et al.
Publicado: (2022)

Dual ET(A)/ET(B) blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension
por: Nadeau, Valerie, et al.
Publicado: (2017)

Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
por: Souza, Rogério, et al.
Publicado: (2022)

Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
por: Mamazhakypov, Argen, et al.
Publicado: (2020)

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension
por: Iglarz, Marc, et al.
Publicado: (2015)

Exploring the failing right ventricle in pulmonary hypertension by cardiac magnetic resonance: An in vivo study utilizing Macitentan
por: Murphy, Gerard, et al.
Publicado: (2022)

The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross‐species comparison of its cytochrome P450 induction pattern
por: Treiber, Alexander, et al.
Publicado: (2020)

The Consistent Effectiveness and Safety of Macitentan Therapies Across Idiopathic and Congenital Heart Disease-Associated PulmonaryArterial Hypertension: A Single-Center Experience
por: Kaymaz, Cihangir, et al.
Publicado: (2022)

Early Diagnosis in Pulmonary Arterial Hypertension: The Search for the Holy Grail
por: Berger, Rolf M. F., et al.
Publicado: (2019)

Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues – a single-centre experience
por: Albinni, Sulaima, et al.
Publicado: (2021)

Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells
por: Gatfield, John, et al.
Publicado: (2012)

COVID-19 and Pulmonary Arterial Hypertension: Early Data and Many Questions
por: Farha, Samar, et al.
Publicado: (2020)

Hit Early and Hit Hard in Pulmonary Arterial Hypertension? Not So Fast!
por: Hassoun, Paul M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dm5j116s69k8nohrbfetafvft4